K
Kaho Shionoya
Researcher at National Institutes of Health
Publications - 11
Citations - 211
Kaho Shionoya is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Biology & Medicine. The author has an hindex of 2, co-authored 5 publications receiving 70 citations. Previous affiliations of Kaho Shionoya include Tokyo University of Science.
Papers
More filters
Journal ArticleDOI
Potential anti-COVID-19 agents, Cepharanthine and Nelfinavir, and their usage for combination treatment.
Hirofumi Ohashi,Hirofumi Ohashi,Koichi Watashi,Wakana Saso,Wakana Saso,Kaho Shionoya,Kaho Shionoya,Shoya Iwanami,Takatsugu Hirokawa,Takatsugu Hirokawa,Tsuyoshi Shirai,Shigehiko Kanaya,Yusuke Ito,Kwang Su Kim,Takao Nomura,Tateki Suzuki,Kazane Nishioka,Kazane Nishioka,Shuji Ando,Keisuke Ejima,Yoshiki Koizumi,Tomohiro Tanaka,Shin Aoki,Kouji Kuramochi,Tadaki Suzuki,Takao Hashiguchi,Katsumi Maenaka,Tetsuro Matano,Tetsuro Matano,Masamichi Muramatsu,Masayuki Saijo,Kazuyuki Aihara,Shingo Iwami,Makoto Takeda,Jane A. McKeating,Takaji Wakita +35 more
TL;DR: In this article, a panel of already approved drugs in a cell culture model of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and identified two new agents having higher antiviral potentials than the drug candidates such as remdesivir and chroloquine in VeroE6/TMPRSS2 cells: the anti-inflammatory drug cepharanthine and human immunodeficiency virus protease inhibitor nelfinavir.
Posted ContentDOI
Multidrug treatment with nelfinavir and cepharanthine against COVID-19
Hirofumi Ohashi,Hirofumi Ohashi,Koichi Watashi,Wakana Saso,Wakana Saso,Kaho Shionoya,Kaho Shionoya,Shoya Iwanami,Takatsugu Hirokawa,Takatsugu Hirokawa,Tsuyoshi Shirai,Shigehiko Kanaya,Yusuke Ito,Kwang Su Kim,Kazane Nishioka,Kazane Nishioka,Shuji Ando,Keisuke Ejima,Yoshiki Koizumi,Tomohiro Tanaka,Shin Aoki,Kouji Kuramochi,Tadaki Suzuki,Katsumi Maenaka,Tetsuro Matano,Tetsuro Matano,Masamichi Muramatsu,Masayuki Saijo,Kazuyuki Aihara,Shingo Iwami,Makoto Takeda,Jane A. McKeating,Takaji Wakita +32 more
TL;DR: This study identifies a new multidrug combination treatment for COVID-19 that combines the HIV protease inhibitor Nelfinavir and the anti-inflammatory drug Cepharanthine to limit SARS-CoV-2 proliferation.
Journal ArticleDOI
Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro
Kaho Shionoya,Kaho Shionoya,Masako Yamasaki,Masako Yamasaki,Shoya Iwanami,Shoya Iwanami,Yusuke Ito,Shuetsu Fukushi,Hirofumi Ohashi,Hirofumi Ohashi,Wakana Saso,Wakana Saso,Tomohiro Tanaka,Shin Aoki,Kouji Kuramochi,Shingo Iwami,Yoshimasa Takahashi,Tadaki Suzuki,Masamichi Muramatsu,Makoto Takeda,Takaji Wakita,Koichi Watashi +21 more
TL;DR: Mefloquine showed higher anti-SARS-CoV-2 activity than Hydroxychloroquine in VeroE6/TMPRSS2 and Calu-3 cells, with IC50 = 1.28 μM, IC90 = 2.31 μM and IC99 = 4.39 μM as discussed by the authors.
Journal ArticleDOI
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2
Hirofumi Ohashi,Takayuki Hishiki,Daisuke Akazawa,Kwang Su Kim,J. Woo,Kaho Shionoya,Kanji Tsuchimoto,Shoya Iwanami,Saya Moriyama,Hitomi Kinoshita,Souichi Yamada,Yudai Kuroda,Tsukasa Yamamoto,Noriko Kishida,Shinji Watanabe,Hideki Hasegawa,Hideki Ebihara,Tadaki Suzuki,Ken Maeda,Shuetsu Fukushi,Yoshimasa Takahashi,Shingo Iwami,Koichi Watashi +22 more
TL;DR: In this paper , the authors quantified the intrinsic sensitivity of BA.2 and BA.1 compared with other variants of concern, Alpha, Gamma, and Delta, to five approved neutralizing antibodies and antiviral drugs.
Posted ContentDOI
Potential anti-monkeypox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments
Daisuke Akazawa,Hirofumi Ohashi,Takayuki Hishiki,Takeshi Morita,Shoya Iwanami,Kwang Su Kim,Yong Dam Jeong,Eun-Sil Park,Michiyo Kataoka,Kaho Shionoya,Junki Mifune,Kanji Tsuchimoto,Shinjiro Ojima,Aa Haeruman Azam,Shogo Nakajima,Hyeongki Park,Tomoki Yoshikawa,Masayuki Shimojima,Kotaro Kiga,Shingo Iwami,Ken Maeda,Tadaki Suzuki,Hideki Ebihara,Yoshimasa Takahashi,Koichi Watashi +24 more
TL;DR: Atovaquone and molnupiravir exhibited pan-Orthopoxvirus activity against vaccinia and cowpox viruses, and data suggest that atovaqu one would be potential candidates for treating monkeypox.